Principal Financial Group Inc Inhibrx, Inc. Transaction History

Principal Financial Group Inc

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Apr 29, 2024	SELL	$32.76 - $39.56 $4,914 - $5,934	-150 Reduced 1.45%	10,218 $357,000
Q4 2023 Feb 07, 2024	SELL	$14.5 - $38.0 $5,843 - $15,314	-403 Reduced 3.74%	10,368 $393,000
Q3 2023 Nov 02, 2023	BUY	$15.75 - $26.31 $6,741 - $11,260	428 Added 4.14%	10,771 $197,000
Q2 2023 Aug 07, 2023	BUY	$16.96 - $27.82 $175,417 - $287,742	10,343 New	10,343 $268,000
Q4 2022 Feb 09, 2023	BUY	$20.18 - $33.33 $200,791 - $331,633	9,950 New	9,950 $245,000
Q1 2022 May 09, 2022	SELL	$19.89 - $43.18 $94,437 - $205,018	-4,748 Closed	0 $0
Q4 2021 Feb 09, 2022	BUY	$26.75 - $46.02 $127,009 - $218,502	4,748 New	4,748 $207,000

25.3K

Ticker INBX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,057,700
Market Cap $626M
Description
Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcin...

Get notified when there are updates to the investment portfolio of Principal Financial Group Inc, based on Form 13F filings with the SEC.

Stay updated on Principal Financial Group Inc with notifications on news.